AstraZeneca profit falls, sees sales growth in ’19

“AstraZeneca PLC (AZN.LN) said Thursday that net profit in the fourth quarter decreased 21% on post-tax adjustments, and guided for product sales growth in the year ahead” writes Carlo Martuscelli for Product sales in China rose 22% at constant exchange rates to $948 million in the quarter, the pharmaceutical company said.The Anglo-Swedish drug maker said net profit for the quarter ended Dec. 31 was $1.03 billion, compared with $1.30 billion the previous-year period.A strong performance from its oncology portfolio buoyed product sales, which were up 8% at constant exchange rates in the period, the FTSE 100-listed company said.

Related posts